Centogene utilizes a comprehensive approach to diagnostics and drug development for rare and neurodegenerative diseases, leveraging its extensive Biodatabank, which houses data from over 850,000 individuals and 400,000 biosamples. The company employs multiomic solutions, including next-generation sequencing (NGS), whole exome sequencing (WES), and whole genome sequencing (WGS), to analyze genetic, transcriptomic, proteomic, and metabolomic data. This integration of omic data allows Centogene to create detailed disease maps that enhance understanding of disease pathways, facilitating the identification of drug targets and biomarkers. Their innovative MOx 2.0 platform, which incorporates RNA sequencing, further revolutionizes precision medicine for patients with rare diseases.

In addition to diagnostics, Centogene provides robust support for pharmaceutical partners in clinical trial operations. Their services encompass patient identification and stratification, epidemiological studies, and biomarker validation, all aimed at streamlining the drug discovery process. By collaborating with over 30 pharmaceutical companies, Centogene helps de-risk drug development through access to real-world evidence and a rich collection of biological samples. Their commitment to advancing research is exemplified by their goal to enable the cure of 100 rare diseases within the next decade, focusing on conditions such as Gaucher Disease, Niemann-Pick Type C Disease, and Parkinson’s Disease.

Germany

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Centogene

Company Details